Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue.

Weingartner R, Oliveira E, Oliveira ES, Sant'Anna UL, Oliveira RP, Azambuja LA, Friedman G

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas1 Dec 1999Cited by 45 (Europe PMC)

PMID10585632DOI10.1590/s0100-879x1999001200009PepBankPUB-10585632

Publisher page PubMedAsk about this study

Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with severe septic shock, methylene blue increased mean arterial pressure from baseline to 60 min.
In plain wordsMethylene blue increased blood pressure compared with baseline in patients with severe septic shock.
Peptide
Methylene blue
Outcome
IncreaseMean arterial pressure
Study
n = 10
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Studied dose
4 mg/kg · intravenous · 1-h infusionAs given in this study (human).
Measurements
Mean arterial pressure
60 mmHg
baseline, median [25-75th percentiles 55-70]
Mean arterial pressure
70 mmHg
60 min, median [25-75th percentiles 65-100]
Source sentences
Summary
Methylene blue administration caused a progressive increase in mean arterial pressure (60 [55-70] to 70 [65-100] mmHg, median [25-75th percentiles]; P<0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the role of nitric oxide in human sepsis, ten patients with severe septic shock requiring vasoactive drug therapy and mechanical ventilation were enrolled in a prospective, open, non-randomized clinical trial to study the acute effects of methylene blue, an inhibitor of guanylate cyclase.
Summary · context
Hemodynamic and metabolic variables were measured before and 20, 40, 60, and 120 min after the start of a 1-h intravenous infusion of 4 mg/kg of methylene blue.
Report a problemFND-1058563201
02HumanNon-randomized trialEfficacy outcome
In patients with severe septic shock, methylene blue increased systemic vascular resistance index from baseline to 60 min.
In plain wordsMethylene blue increased blood vessel resistance compared with baseline in patients with severe septic shock.
Peptide
Methylene blue
Outcome
IncreaseSystemic vascular resistance index
Study
n = 10
Comparator
Baseline
Outcome group
Vascular function · Cardiovascular
Studied dose
4 mg/kg · intravenous · 1-h infusionAs given in this study (human).
Measurements
Systemic vascular resistance index
649 dyne s-1 cm-5 m-2
baseline, median [25-75th percentiles 479-1084]
Systemic vascular resistance index
1066 dyne s-1 cm-5 m-2
60 min, median [25-75th percentiles 585-1356]
Source sentences
Summary
systemic vascular resistance index (649 [479-1084] to 1066 [585-1356] dyne s-1 cm-5 m-2; P<0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the role of nitric oxide in human sepsis, ten patients with severe septic shock requiring vasoactive drug therapy and mechanical ventilation were enrolled in a prospective, open, non-randomized clinical trial to study the acute effects of methylene blue, an inhibitor of guanylate cyclase.
Summary · context
Hemodynamic and metabolic variables were measured before and 20, 40, 60, and 120 min after the start of a 1-h intravenous infusion of 4 mg/kg of methylene blue.
Report a problemFND-1058563202
03HumanNon-randomized trialEfficacy outcome
In patients with severe septic shock, methylene blue increased left ventricular stroke work index from baseline to 60 min.
In plain wordsMethylene blue increased left heart pumping work compared with baseline in patients with severe septic shock.
Peptide
Methylene blue
Outcome
IncreaseLeft ventricular stroke work index
Study
n = 10
Comparator
Baseline
Outcome group
Heart function · Cardiovascular
Studied dose
4 mg/kg · intravenous · 1-h infusionAs given in this study (human).
Measurements
Left ventricular stroke work index
35 g m-1 m-2
baseline, median [25-75th percentiles 27-47]
Left ventricular stroke work index
38 g m-1 m-2
60 min, median [25-75th percentiles 32-56]
Source sentences
Summary
the left ventricular stroke work index (35 [27-47] to 38 [32-56] g m-1 m-2; P<0.05) from baseline to 60 min.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the role of nitric oxide in human sepsis, ten patients with severe septic shock requiring vasoactive drug therapy and mechanical ventilation were enrolled in a prospective, open, non-randomized clinical trial to study the acute effects of methylene blue, an inhibitor of guanylate cyclase.
Summary · context
Hemodynamic and metabolic variables were measured before and 20, 40, 60, and 120 min after the start of a 1-h intravenous infusion of 4 mg/kg of methylene blue.
Report a problemFND-1058563203
04HumanNon-randomized trialEfficacy outcome
In patients with severe septic shock, pulmonary vascular resistance index increased after 20 min of methylene blue.
In plain wordsMethylene blue increased lung blood vessel resistance compared with baseline in patients with severe septic shock.
Peptide
Methylene blue
Outcome
IncreasePulmonary vascular resistance index
Study
n = 10
Comparator
Baseline
Outcome group
Vascular function · Cardiovascular
Studied dose
4 mg/kg · intravenous · 1-h infusionAs given in this study (human).
Measurements
Pulmonary vascular resistance index
150 dyne s-1 cm-5 m-2
baseline, median [25-75th percentiles 83-207]
Pulmonary vascular resistance index
186 dyne s-1 cm-5 m-2
20 min, median [25-75th percentiles 121-367]
Source sentences
Summary
The pulmonary vascular resistance index increased from 150 [83-207] to 186 [121-367] dyne s-1 cm-5 m-2 after 20 min (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the role of nitric oxide in human sepsis, ten patients with severe septic shock requiring vasoactive drug therapy and mechanical ventilation were enrolled in a prospective, open, non-randomized clinical trial to study the acute effects of methylene blue, an inhibitor of guanylate cyclase.
Summary · context
Hemodynamic and metabolic variables were measured before and 20, 40, 60, and 120 min after the start of a 1-h intravenous infusion of 4 mg/kg of methylene blue.
Report a problemFND-1058563204
05HumanNon-randomized trialEfficacy outcome
In patients with severe septic shock, mixed venous oxygen saturation decreased after 60 min of methylene blue.
In plain wordsMethylene blue reduced oxygen saturation in venous blood compared with baseline in patients with severe septic shock.
Peptide
Methylene blue
Outcome
DecreaseMixed venous saturation
Study
n = 10
Comparator
Baseline
Outcome group
Respiratory function · Respiratory
Studied dose
4 mg/kg · intravenous · 1-h infusionAs given in this study (human).
Measurements
Mixed venous saturation
65%
baseline, median [25-75th percentiles 56-76]
Mixed venous saturation
63%
60 min, median [25-75th percentiles 55-69]
Source sentences
Summary
Mixed venous saturation decreased from 65 [56-76] to 63 [55-69]% (P<0.05) after 60 min.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the role of nitric oxide in human sepsis, ten patients with severe septic shock requiring vasoactive drug therapy and mechanical ventilation were enrolled in a prospective, open, non-randomized clinical trial to study the acute effects of methylene blue, an inhibitor of guanylate cyclase.
Summary · context
Hemodynamic and metabolic variables were measured before and 20, 40, 60, and 120 min after the start of a 1-h intravenous infusion of 4 mg/kg of methylene blue.
Report a problemFND-1058563205
06HumanNon-randomized trialEfficacy outcome
In patients with severe septic shock, the PaO2/FiO2 ratio decreased after 40 min of methylene blue.
In plain wordsMethylene blue reduced the blood oxygen to inhaled oxygen ratio compared with baseline in patients with severe septic shock.
Peptide
Methylene blue
Outcome
DecreasePaO2/FiO2 ratio
Study
n = 10
Comparator
Baseline
Outcome group
Respiratory function · Respiratory
Studied dose
4 mg/kg · intravenous · 1-h infusionAs given in this study (human).
Measurements
PaO2/FiO2 ratio
168 mmHg
baseline, median [25-75th percentiles 131-215]
PaO2/FiO2 ratio
132 mmHg
40 min, median [25-75th percentiles 109-156]
Source sentences
Summary
The PaO2/FiO2 ratio decreased from 168 [131-215] to 132 [109-156] mmHg (P<0.05) after 40 min.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the role of nitric oxide in human sepsis, ten patients with severe septic shock requiring vasoactive drug therapy and mechanical ventilation were enrolled in a prospective, open, non-randomized clinical trial to study the acute effects of methylene blue, an inhibitor of guanylate cyclase.
Summary · context
Hemodynamic and metabolic variables were measured before and 20, 40, 60, and 120 min after the start of a 1-h intravenous infusion of 4 mg/kg of methylene blue.
Report a problemFND-1058563206
07HumanNon-randomized trialEfficacy outcome
In patients with severe septic shock, arterial lactate concentration decreased after 60 min of methylene blue.
In plain wordsMethylene blue reduced arterial blood lactate compared with baseline in patients with severe septic shock.
Peptide
Methylene blue
Outcome
DecreaseArterial lactate concentration
Study
n = 10
Comparator
Baseline
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
4 mg/kg · intravenous · 1-h infusionAs given in this study (human).
Measurements
Arterial lactate concentration
5.1 mmol/l
baseline, mean (SD 2.9)
Arterial lactate concentration
4.5 mmol/l
60 min, mean (SD 2.1)
Source sentences
Summary
Arterial lactate concentration decreased from 5.1 +/- 2.9 to 4.5 +/- 2.1 mmol/l, mean +/- SD (P<0.05) after 60 min.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the role of nitric oxide in human sepsis, ten patients with severe septic shock requiring vasoactive drug therapy and mechanical ventilation were enrolled in a prospective, open, non-randomized clinical trial to study the acute effects of methylene blue, an inhibitor of guanylate cyclase.
Summary · context
Hemodynamic and metabolic variables were measured before and 20, 40, 60, and 120 min after the start of a 1-h intravenous infusion of 4 mg/kg of methylene blue.
Report a problemFND-1058563207
08HumanNon-randomized trialEfficacy outcome
In patients with severe septic shock, heart rate did not change after methylene blue.
In plain wordsHeart rate did not change from baseline after methylene blue in patients with severe septic shock.
Peptide
Methylene blue
Outcome
No significant changeHeart rate
Study
n = 10
Comparator
Baseline
Outcome group
Heart function · Cardiovascular
Studied dose
4 mg/kg · intravenous · 1-h infusionAs given in this study (human).
Source sentences
Summary
Heart rate, cardiac filling pressures, cardiac output, oxygen delivery and consumption did not change.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the role of nitric oxide in human sepsis, ten patients with severe septic shock requiring vasoactive drug therapy and mechanical ventilation were enrolled in a prospective, open, non-randomized clinical trial to study the acute effects of methylene blue, an inhibitor of guanylate cyclase.
Summary · context
Hemodynamic and metabolic variables were measured before and 20, 40, 60, and 120 min after the start of a 1-h intravenous infusion of 4 mg/kg of methylene blue.
Report a problemFND-1058563208
09HumanNon-randomized trialEfficacy outcome
In patients with severe septic shock, cardiac filling pressures did not change after methylene blue.
In plain wordsHeart filling pressures did not change from baseline after methylene blue in patients with severe septic shock.
Peptide
Methylene blue
Outcome
No significant changeCardiac filling pressures
Study
n = 10
Comparator
Baseline
Outcome group
Heart function · Cardiovascular
Studied dose
4 mg/kg · intravenous · 1-h infusionAs given in this study (human).
Source sentences
Summary
Heart rate, cardiac filling pressures, cardiac output, oxygen delivery and consumption did not change.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the role of nitric oxide in human sepsis, ten patients with severe septic shock requiring vasoactive drug therapy and mechanical ventilation were enrolled in a prospective, open, non-randomized clinical trial to study the acute effects of methylene blue, an inhibitor of guanylate cyclase.
Summary · context
Hemodynamic and metabolic variables were measured before and 20, 40, 60, and 120 min after the start of a 1-h intravenous infusion of 4 mg/kg of methylene blue.
Report a problemFND-1058563209
10HumanNon-randomized trialEfficacy outcome
In patients with severe septic shock, cardiac output did not change after methylene blue.
In plain wordsHeart blood output did not change from baseline after methylene blue in patients with severe septic shock.
Peptide
Methylene blue
Outcome
No significant changeCardiac output
Study
n = 10
Comparator
Baseline
Outcome group
Heart function · Cardiovascular
Studied dose
4 mg/kg · intravenous · 1-h infusionAs given in this study (human).
Source sentences
Summary
Heart rate, cardiac filling pressures, cardiac output, oxygen delivery and consumption did not change.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the role of nitric oxide in human sepsis, ten patients with severe septic shock requiring vasoactive drug therapy and mechanical ventilation were enrolled in a prospective, open, non-randomized clinical trial to study the acute effects of methylene blue, an inhibitor of guanylate cyclase.
Summary · context
Hemodynamic and metabolic variables were measured before and 20, 40, 60, and 120 min after the start of a 1-h intravenous infusion of 4 mg/kg of methylene blue.
Report a problemFND-1058563210
11HumanNon-randomized trialEfficacy outcome
In patients with severe septic shock, oxygen delivery did not change after methylene blue.
In plain wordsOxygen delivery did not change from baseline after methylene blue in patients with severe septic shock.
Peptide
Methylene blue
Outcome
No significant changeOxygen delivery
Study
n = 10
Comparator
Baseline
Outcome group
Blood oxygenation and oxygen transport · Whole body
Studied dose
4 mg/kg · intravenous · 1-h infusionAs given in this study (human).
Source sentences
Summary
Heart rate, cardiac filling pressures, cardiac output, oxygen delivery and consumption did not change.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the role of nitric oxide in human sepsis, ten patients with severe septic shock requiring vasoactive drug therapy and mechanical ventilation were enrolled in a prospective, open, non-randomized clinical trial to study the acute effects of methylene blue, an inhibitor of guanylate cyclase.
Summary · context
Hemodynamic and metabolic variables were measured before and 20, 40, 60, and 120 min after the start of a 1-h intravenous infusion of 4 mg/kg of methylene blue.
Report a problemFND-1058563211
12HumanNon-randomized trialEfficacy outcome
In patients with severe septic shock, oxygen consumption did not change after methylene blue.
In plain wordsOxygen consumption did not change from baseline after methylene blue in patients with severe septic shock.
Peptide
Methylene blue
Outcome
No significant changeOxygen consumption
Study
n = 10
Comparator
Baseline
Outcome group
Blood oxygenation and oxygen transport · Whole body
Studied dose
4 mg/kg · intravenous · 1-h infusionAs given in this study (human).
Source sentences
Summary
Heart rate, cardiac filling pressures, cardiac output, oxygen delivery and consumption did not change.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the role of nitric oxide in human sepsis, ten patients with severe septic shock requiring vasoactive drug therapy and mechanical ventilation were enrolled in a prospective, open, non-randomized clinical trial to study the acute effects of methylene blue, an inhibitor of guanylate cyclase.
Summary · context
Hemodynamic and metabolic variables were measured before and 20, 40, 60, and 120 min after the start of a 1-h intravenous infusion of 4 mg/kg of methylene blue.
Report a problemFND-1058563212
13HumanNon-randomized trialSafety outcome
In patients with severe septic shock, no adverse effect was observed during methylene blue administration.
In plain wordsNo adverse effect was observed during methylene blue administration in patients with severe septic shock.
Peptide
Methylene blue
Outcome
Not applicableAdverse effects
Study
n = 10
Outcome group
Adverse events · Whole body
Studied dose
4 mg/kg · intravenous · 1-h infusionAs given in this study (human).
Source sentences
Summary
Methylene blue administration was safe and no adverse effect was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the role of nitric oxide in human sepsis, ten patients with severe septic shock requiring vasoactive drug therapy and mechanical ventilation were enrolled in a prospective, open, non-randomized clinical trial to study the acute effects of methylene blue, an inhibitor of guanylate cyclase.
Summary · context
Hemodynamic and metabolic variables were measured before and 20, 40, 60, and 120 min after the start of a 1-h intravenous infusion of 4 mg/kg of methylene blue.
Report a problemFND-1058563213

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.